Animal Diseases: Clinical Trials

75 trials for Animal Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

55 completed, 7 recruiting, 5 active not recruiting, 4 terminated. 75 Phase 2, 18 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 275Completed 55, Recruiting 7, Active not recruiting 5, Terminated 4, Unknown 2, Not yet recruiting 1, Withdrawn 1
Phase 118Completed 16, Recruiting 1, Terminated 1
Phase 34Completed 3, Unknown 1

Follow Animal Diseases: new trials by email Literature Review of Animal Diseases trials Research Report on Animal Diseases

Trials (filtered) newest first · largest first

All 75 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Topical Rebamipide Versus Topical Betamethasone for Treatment of Oral Aphthous Ulcers
Rebamipide mouthwash, Betamethasone mouthwash - Oral Aphthous Ulcers
Phase 2RecruitingCairo University462026-07-012026-10-06
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
BNT166a, Placebo - Mpox (Monkeypox), Smallpox
Phase 2RecruitingBioNTech SE3102026-02-202026-08-11
The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
Echinacea Extract - Cryptosporidium Infection
Phase 2RecruitingAl-Azhar University602026-01-182026-02-05
Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo
MVA-SIBP low dose, MVA-SIBP high dose, MVA-BN - Monkeypox (Mpox)
Phase 2Not yet recruitingShanghai Institute Of Biological Products1802025-12-312025-11-28
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
Cryptosporidium parvum oocysts (ABO809), EDI048, Placebo - Cryptosporidiosis
Phase 2RecruitingNovartis Pharmaceuticals802025-12-082026-11-10
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Jynneos, MVA-BN (Quail) - Monkeypox (Mpox)
Phase 2Active not recruitingBavarian Nordic9702025-10-272026-04-08
Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults
Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg, Monovalent influenza vaccine type A (H5N8) 15 mcg, Placebo - Avian Influenza A Virus
Phase 1 / Phase 2RecruitingButantan Institute7002025-09-102026-04-02
An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC
Mpox vaccination with MVA-BN - Mpox (Monkeypox)
Phase 2Active not recruitingInstitute of Tropical Medicine, Belgium6002025-08-042026-05-19
Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)
ChAdOx1 RVF, Rabies Vaccine - Rift Valley Fever
Phase 2Active not recruitingUniversity of Oxford2402025-07-082025-11-17
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
cAd3-Marburg Vaccine, Placebo - Marburg Virus Disease
Phase 2Active not recruitingAlbert B. Sabin Vaccine Institute2002025-04-142026-09-10
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
MVA-BN - Monkeypox (Mpox)
Phase 2Active not recruitingBavarian Nordic4602024-10-212025-11-24
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
Tafenoquine, Placebo - Babesiosis
Phase 2Recruiting60 Degrees Pharmaceuticals LLC332024-06-172025-11-21
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3. - Influenza, Human
Phase 1 / Phase 2CompletedGlaxoSmithKline9912024-04-182026-02-05
Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults
cAd3-Marburg vaccine, Placebo - Marburg Virus Disease
Phase 2CompletedAlbert B. Sabin Vaccine Institute1262023-10-192025-07-23
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
BNT166a - Monkeypox
Phase 1 / Phase 2CompletedBioNTech SE962023-09-212026-09-15
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
mRNA-1769, Placebo - Smallpox, Mpox
Phase 1 / Phase 2CompletedModernaTX, Inc.3512023-08-152025-07-16
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
JYNNEOS - Monkeypox
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)4502023-03-222026-03-27
Tecovirimat for Treatment of Monkeypox Virus
Tecovirimat Oral Capsule, Placebo - Monkeypox
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)5972022-10-102025-10-09
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
JYNNEOS - Monkeypox
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)2292022-09-092026-04-16
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
aH5N6c on Day 1, aH5N6c on Day 22, Placebo on Day 22 - Influenza, Human, Influenza in Birds
Phase 2CompletedSeqirus2602022-07-182026-05-13

Showing 20 of 75. Sign in to see all of them.

Narrower conditions

Influenza in Birds (40)  ·  Influenza, Human (32)  ·  Mpox, Monkeypox (12)  ·  Cryptosporidiosis (7)  ·  Rift Valley Fever (5)  ·  Virus Diseases (5)  ·  HIV Infections (4)  ·  Orthomyxoviridae Infections (4)  ·  Foot-and-Mouth Disease (3)  ·  Smallpox (3)  ·  AIDS-Related Opportunistic Infections (2)  ·  Arbovirus Infections (2)  ·  Colorectal Neoplasms (2)  ·  Furunculosis (2)  ·  Hemorrhagic Fevers, Viral (2)

Broader conditions

Infections (73)  ·  Virus Diseases (62)  ·  RNA Virus Infections (52)  ·  Bird Diseases (41)  ·  Orthomyxoviridae Infections (36)  ·  Respiratory Tract Diseases (30)  ·  Respiratory Tract Infections (30)  ·  Digestive System Diseases (14)  ·  Primate Diseases (14)  ·  DNA Virus Infections (13)  ·  Poxviridae Infections (12)  ·  Rodent Diseases (12)  ·  Gastrointestinal Diseases (9)  ·  Intestinal Diseases (9)

Interventions

smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (7)  ·  Influenza Vaccines (5)  ·  MF59 oil emulsion (3)  ·  AS03 adjuvant (2)  ·  Adjuvants, Pharmaceutic (2)  ·  Aluminum Hydroxide (2)  ·  Oseltamivir (2)  ·  Rabies Vaccines (2)  ·  nitazoxanide (2)  ·  Betamethasone (1)  ·  Blood Component Removal (1)  ·  Clofazimine (1)  ·  Colchicine (1)  ·  Desiccation (1)  ·  Echinacea extract (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (27)  ·  Novartis Vaccines (7)  ·  U.S. Army Medical Research and Development Command (4)  ·  Alachua Government Services, Inc. (3)  ·  Albert B. Sabin Vaccine Institute (2)  ·  Bavarian Nordic (2)  ·  BioNTech SE (2)  ·  Biomedical Advanced Research and Development Authority (2)  ·  60 Degrees Pharmaceuticals LLC (1)  ·  Al-Azhar University (1)  ·  Butantan Institute (1)  ·  Cairo University (1)  ·  Eastern Virginia Medical School (1)  ·  Elena Gonzalez Brant, MD (1)  ·  Enimmune Corporation (1)

Countries

United States (42)  ·  Thailand (6)  ·  Democratic Republic of the Congo (4)  ·  Australia (3)  ·  Finland (3)  ·  United Kingdom (3)  ·  China (2)  ·  Egypt (2)  ·  Japan (2)  ·  Kenya (2)  ·  Puerto Rico (2)  ·  Russia (2)  ·  Singapore (2)  ·  South Africa (2)  ·  Uganda (2)

Top investigators

Alexander Geisberger, MD (1)  ·  Arthur White (1)  ·  Bob Taylor, MD (1)  ·  Carey J (1)  ·  Carlos Fierro, MD (1)  ·  Denise Yardley, MD (1)  ·  Elena M Gonzalez Brant, MD (1)  ·  Fichtenbaum C (1)  ·  Gerald Aichinger, MD (1)  ·  H. Clifford Lane, M.D. (1)

Results publications

PMID 39756216, PMID 30968056, PMID 18237269, PMID 18260764, PMID 18808338, PMID 19416838, PMID 19569973, PMID 20810680, PMID 20819892, PMID 21282194, PMID 21386997, PMID 21606530, PMID 22777094, PMID 23536690, PMID 23650416, PMID 23723457, PMID 24041789, PMID 24047817, PMID 28533093, PMID 29261658, PMID 30139372, PMID 30955980, PMID 31194712, PMID 31399275, PMID 31812464, PMID 32277809, PMID 33091433, PMID 34174187, PMID 34711436, PMID 34748385, PMID 35465983, PMID 37466221, PMID 38366591, PMID 38537255, PMID 39798434, PMID 40239067, PMID 41319397, PMID 42235570, PMID 42372625, PMID 42532635, PMID 42630599

NIH funding

2009 (1), R01AI041735 (1), U19AI090023 (1)